AbCellera Biologics Inc. (ABCL) Net margin 2019–2025
AbCellera Biologics Inc. (ABCL) net profit margin by fiscal year — reported net income divided by reported revenue.
-194.9%FY2025 · since FY2019: -19.0% → -194.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -194.9% | +369.9 pp |
| FY2024 | -564.8% | -179.8 pp |
| FY2023 | -385.0% | -417.7 pp |
| FY2022 | 32.7% | -8.2 pp |
| FY2021 | 40.9% | -10.1 pp |
| FY2020 | 51.0% | +70.0 pp |
| FY2019 | -19.0% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More ABCL financial trends
ABCL RevenueABCL Net incomeABCL Gross profitABCL Gross marginABCL Operating incomeABCL Operating marginABCL Operating cash flowABCL Free cash flowABCL Capital expendituresABCL Return on equityABCL Stock buybacksABCL Dividends paidABCL Total assetsABCL Total liabilitiesABCL Shareholders’ equityABCL overview →